Akeso and Summit Therapeutics’ ivonescimab reduced the risk of death by 27% compared with Keytruda in patients with treatment ...

The ink was barely dry on the FDA approval letter for AstraZeneca’s Etcamah before the oral SERD suffered a key clinical ...

The fact that Gilead Sciences’ Trodelvy failed as a first-line treatm | Newly revealed global phase 3 data from Merck and ...

Takeda's long-time R&D chief Andy Plump will retire. Daiichi Sankyo beat back a $1.3 billion damage claim in a lawsuit.

Following formal sign-off from the FDA, Handa Pharmaceuticals’ branded drug reformulation strategy has paid off for a third ...

In his first interview after taking the reins of the FDA’s Oncology Center of Excellence (OCE), Angelo de Claro, M.D., is ...

With positive phase 3 results in hand, AbbVie is one step closer to expanding the reach of its key migraine preventative ...

In a series of moves by Switzerland-headquartered CDMOs this week, manufacturing powerhouse Lonza is doubling down on its US ...

Bayer has won first-line approval for its tyrosine kinase inhibitor, Hyrnuo, in patients with HER2-mutant non-small cell lung ...

Argonaut Manufacturing Services, a CDMO specializing in aseptic fill-finish for injectable biologics and other drugs, has ...

Caris Life Sciences is signing up Hollywood legend Kevin Costner to break down the importance of early cancer detection—and ...

Following a monthslong interregnum at the U.S. Food and Drug Administration, the leadership pieces are again locking into ...